Objectives-To examine the clinical course of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in a prospective study, after the initial two months. Methods-Seventy four patients with PMRIGCA were foliowed for a median of 60 weeks. Detailed clinical and laboratory records were made on each visit. Results-Twenty per cent of patients with PMR developed GCA and 24% of patients with GCA developed PMR from the onset of symptoms. After two months, most patients experienced at least one relapse. Relapses and persistence of abnormal symptoms and signs were most common in patients with both PMR and GCA and least common in those with GCA alone. Relapses were most common in the first year and 54% occurred in association with steroid reduction. Major complications were rare. Laboratory parameters and temporal artery histology were not helpful in predicting relapse. Only 24% ofpatients were able to stop steroid treatment after two years.
The earliest case reports of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) It is well recognised that relapses, including loss of vision, can occur in patients who are well controlled on corticosteroids. 7 14 The reported incidence of relapse ranges from 4-87% of patients and many experience more than one episode.5 8-1 13 15-9 Most relapses were related to steroid reduction;5 16 in one study the disease spontaneously became active. 9 In two studies patients with PMR tended to have PMR flaresl' 17 but in another, 55% of PMR patients went on to develop GCA and 26% developed visual or neurological complications. '8 Other groups reported that patients with either PMR or GCA usually had polymyalgic flares8 and that GCA patients had both polymyalgic and arteritic flares.'7 Most groups agreed that relapses were more common during the first year of treatment. Two studies reported that the ESR was evaluated during 700/o8 and i00%'5 of relapses. Once treatment was discontinued, the reported relapse rate ranged from 4-430/o.6 9 17 Patients tended to relapse within one year of stopping prednisolone8 9 '7 but relapses after 10 years occurred. 8 There is considerable variation in the reported frequency and nature of relapses. It is not clear why relapses occur, nor whether they can be predicted. The aim of this prospective study was to follow patients with PMR alone, GCA alone and with both conditions and document the course of their disease, with particular emphasis on relapses in each patient subgroup.
Patients and methods Seventy four patients with active untreated PMR/GCA were followed up for a median of 60 weeks. All fulfilled the diagnostic criteria of Jones and Hazleman (Appendix). 18 onset, usually because of the development of GCA symptoms some months after the onset of PMR. GCA preceded PMR in only two patients with both PMR and GCA.
There were 847 patient visits in total, with a range of 2-33 visits/patient (mean 11, SE 0 72). The mean length of follow up was similar in all three groups. Two patients (5%) with PMR developed GCA after the first two months of treatment; one at 26 weeks and one at 89 weeks (six also developed GCA within the first two months of treatment).20 Four patients with GCA developed PMR (24%) at 15, 27, 67 and 75 weeks after starting treatment.
The clinical course within the first two months of treatment has been discussed in a previous paper comparing different steroid regimes.20 Two patients were followed up for only eight weeks and one woman with florid GCA died at home at eight weeks. Follow up data was therefore available on 71 patients (39 PMR, 16 GCA, 16 'Both') after two months, with 4729 patient weeks of follow up and 574 patient visits. Patients with 'Both' were reviewed on a mean of ten occasions, PMR 7.5 visits and GCA 7-7 visits. There were 77 observed relapses in 43 patients (60%) after the first two months -24 PMR (61%), eight GCA (25%)), 11 'Both' (50%). Forty one relapses between visits were reported by patients who had increased their prednisolone dose and were well when seen at the next visit. Thus only 27% of patients did not experience a relapse after the first two months. Most patients (77%) were observed to experience one or two relapses after two months but 10 had three or more (table 1) .
In addition, there were 32 subsequent visits where symptoms remained as severe, that is, 101 Grade 1 visits. There were 74 visits after the initial two months when patients had improved from a relapse but were still not back to normal (Grade 2 visits).
There were significantly fewer abnormal visits (Grade 1 and Grade 2) in patients with GCA only (p < 0-0 1). This difference held when abnormal visits were considered as a percentage of weeks of follow up. If the relapse rate was considered with respect to the final diagnosis rather than the diagnosis on presentation, the same pattern was seen. Four patients (two PMR, two Both) accounted for 60 abnormal visits (Grade 1 and 2) but even if these atypical patients were excluded, patients with GCA alone had the fewest relapses and abnormal visits.
One patient with both PMR and GCA lost the sight in one eye while on treatment; ESR The clinical and laboratory course ofpolymyalgia rheumatica/giant cell arteritis after the first two months of treatment was not related to the histology on temporal artery biopsy. No patient with PMR evolved into rheumatoid arthritis during the period of follow up. One patient has subsequently developed seronegative polyarthritis. Possibly the initial strict exclusion of patients with peripheral joint involvement reduced the inclusion of polymyalgia polyarthritis.
Seven patients managed to discontinue steroid treatment. One further patient came off steroids at 70 weeks but had a relapse with features of myalgia and arteritis at 100 weeks. Thus 24% of patients followed for 18 months to two years had discontinued steroids at a mean cumulative dose of 3 16 g. By the end of the study a further 39 patients had exceeded this dose and were still requiring steroids.
The ESR and CRP during follow up have been discussed in an earlier paper;2' The ESR was found to correlate better than CRP with relapses. Orosomucoid and haptoglobin levels were slightly elevated during 40% relapses but in almost half the patients, values were chronically mildly elevated. A minimal increase in cx1 antitrypsin was seen in 27% relapses.
Immune complexes were elevated in 10% of new relapses and alkaline phosphatase was abnormal in only five relapses. Immunoglobulin G was elevated in three relapses, IgA in one and IgM in four.
Discussion
This study suggests that PMR/GCA runs a benign course in most patients but at least one episode or relapse was common. Serious complications were rare. Although 20% of patients with PMR developed GCA after treatment was started, three quarters did so within the first five weeks. It would be prudent to review patients frequently in the first eight weeks of treatment, so that the development of GCA would be detected rapidly. The low incidence of late development of GCA is reassuring. Definition of relapse is inevitably subjective and in this study a pragmatic view was taken: a recurrence of symptoms severe enough to warrant an increase in prednisolone dose was defined as relapse, irrespective of the ESR or CRP. Almost all patients were directly referred by their general practitioners who would normally have managed at least half of these cases at home. This study therefore is closer to a true population study than most. This may partly account for the lower incidence of serious complications compared with other retrospective studies. A previous study in the same hospital'8 found a much higher complication rate, probably because it dealt with a selected population many of whom had been seen by physicians, neurologists or ophthalmologists, and who may have had a more aggresslve dilsease.
We confirmed the finding of other studies that relapses were most frequent within the first few months after diagnosis. About half of the relapses occurred in relation to attempted steroid reduction usually at a dose of around 10 mg. We suggest that clinicians should review patients more frequently when reduction below 10 mg of prednisolone is attempted.
Patients with both GCA and PMR had more frequent relapses and persistence of symptoms, and the difference was most striking when compared with those with GCA only. This has not been documented previously although most studies have not separated GCA alone from GCA with PMR and thus may have missed this observation. These patients were more likely to experience arteritic flares, so.the phenomenon of 'pseudorheumatism', seen on steroid reduction, was not the explanation for the increased number of abnormal visits in this group. The number of visits/patient and mean follow up was not significantly different in each subgroup, so these findings are not due to unwell patients being seen more often. The initial response to steroid treatment when higher doses were used was rapid in most cases; relatively small increases in prednisolone dose were given during relapses and it is possible that a larger increase would have led to more rapid recovery. There was no evidence that the different initial treatment regimes influenced relapses later in any subgroup. Some patients, especially those with PMR, preferred to tolerate mild symptoms rather than increase their steroids further.
We examined the data to see if particular characteristics such as age, temporal artery histology, initial ESR or other laboratory features such as, alkaline phosphatase predicted relapse, but found no such association. About a third of patients with 'Both' had symptoms for over a year before treatment; numbers in this group were small and did not appear to be more at risk of relapse.
The acute phase proteins were not of value in assessing disease activity, and the results support an earlier study22 where orosomucoid and haptoglobin but not ESR tended to remain elevated despite clinical improvement. Elevation of alkaline phosphatase or immune complexes was rare after treatment was started.
The number of patients able to discontinue steroids was small and could not be formally analysed, but no clinical or laboratory features appeared to predict the early withdrawal of steroids. Our results support the European view that treatment is needed for at least two years in most cases. Longer follow up would be helpful in future studies to clarify the length of treatment needed and the frequency of later relapses.
